HIGHLIGHTS
- who: Rodney P. Rocconi from the University of Alabama at Birmingham, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Mobile, Gradalis, Inc have published the research: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer, in the Journal: (JOURNAL)
- what: The authors demonstrate that high expression of a gene named ENTPD1/CD39 predicts a positive response to Vigil therapy. This study explores the relationship of mRNA expression via NanoString analysis in harvested baseline tumor to RFS and OS in Vigil treated patients from . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.